A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.

Authors :: Desai, Jayesh
Davar, Diwakar
Deva, Sanjeev
Gao, Bo
Liu, Tianshu
Matos, Marco
Meniawy, Tarek
O'Byrne, Kenneth John
Sun, Meili
Voskoboynik, Mark
Yang, Kunyu
Yu, Xinmin
Chen, Xin
Dong, Yan
Giovinazzo, Hugh
Leaw, Shiangjiin
Patel, Deepa
Rahman, Tahmina
Wu, Yanjie
Day, Daphne
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p2574-2574, 1p
Publication Year :: 2023

Full Text Access

Tools